Reuters logo
BRIEF-Pfizer says FDA accepted supplemental NDA for ulcerative colitis treatment
July 13, 2017 / 12:29 PM / 5 months ago

BRIEF-Pfizer says FDA accepted supplemental NDA for ulcerative colitis treatment

July 13 (Reuters) - Pfizer Inc:

* Pfizer announces FDA accepts supplemental new drug application for xeljanz® (tofacitinib citrate) for the treatment of adult patients with moderately to severely active ulcerative colitis

* Pfizer Inc - ‍FDA has provided an anticipated prescription drug user fee act (pdufa) action date in March 2018 for SNDA​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below